Health-Related Quality of Life in the CARTITUDE-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma
Thomas Martin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Sundar Jagannath(Mount Sinai Hospital), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Yunsi Olyslager(Janssen (Belgium)), Deepu Madduri(Johnson & Johnson (United States)), Mounzer Agha(Dana-Farber Cancer Institute), Myo Htut(City Of Hope National Medical Center), Adam D. Cohen(Penn Center for AIDS Research), Parameswaran Hari(Medical College of Wisconsin), Yi Lin(Mayo Clinic), Jesús G. Berdeja(Tennessee Oncology), Marlene J. Carrasco-Alfonso, Alicia J. Allred(Queen's University Belfast), Andrzej Jakubowiak(University of Chicago Medical Center), Farah Hossain, John Fastenau(Janssen (United States)), Katharine S. Gries(Johnson & Johnson (United States)), Jordan M. Schecter(Centro de Investigación del Cáncer), William Deraedt(Janssen (Belgium)), Muhammad Akram(Unknown), Xiaoling Wu(South China University of Technology), Tzu‐Min Yeh(Centro de Investigación del Cáncer), Jenna D. Goldberg(Memorial Sloan Kettering Cancer Center), A. Keith Stewart, Arnob Banerjee(Johnson & Johnson (United States)), Carolyn C. Jackson(Centro de Investigación del Cáncer)
Cited by 3
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Awareness and current knowledge of breast cancer
|Biological Research|2017|1.4k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k